Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows

Nuo Therapeutics, Inc.

Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.
Aurix branded product revenue rose over 30% sequentially versus Q4 2025.
Net operating loss improved to $446,000 from $745,000 in Q1 2025.
Entered $1.0M Loan and Security Agreement to fund growth as company approaches breakeven.
CEO cites strong Aurix demand and favorable Medicare reimbursement shift for autologous PRP.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuo Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue approximately $1.3 million.

Period: the first quarter ended March 31, 2026
Revenue: approximately $1.3 million
Result: reported results

Exact text from the filing

results for the first quarter ended March 31, 2026 and provided an operational and business update. First Quarter 2026 Financial Summary ● Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year’s fourth quarter ● Aurix branded product revenues were

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-017116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.